Impact of augmented reality and virtual reality on mathematical learning in students with ASD and ADHD
Maskana · 30.06.2026 · 17 (1) · 59-71
DOI: 10.18537/mskn.17.01.04 ↗Kurz gefasst
Fachartikel in der Zeitschrift Maskana, online erschienen am 30.06.2026. Verfasst von Celia Gallardo Herrerias. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
The impact of Augmented Reality (AR) and Virtual Reality (VR) technologies on primary school students with Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) in math learning is discussed in this study. Using a mixed-methods quasi-experimental design, 60 primary school students (30 ASD, 30 ADHD) were assigned to experimental (AR/VR) and control (traditional instruction) groups. The 8-week intervention had intensive math experience based on the sensory and cognitive needs, pre- and post-tests measuring the calculation and problem-solving capacity. Outcomes indicated that in the experimental group, ADHD students achieved a 30% increase in math scores and in motivation (+30%) and sustained attention (+25%). Interactive and engaging AR/VR environments reduced distractibility and enhanced engagement, according to teachers. ASD students moderately improved (15–18%), showing that additional customization was needed to accommodate sensory sensitivities.
Zitieren
APA
Herrerias, C. G. (2026). Impact of augmented reality and virtual reality on mathematical learning in students with ASD and ADHD. Maskana, 17(1), 59-71. https://doi.org/10.18537/mskn.17.01.04
Vancouver
Herrerias CG. Impact of augmented reality and virtual reality on mathematical learning in students with ASD and ADHD. Maskana. 2026;17(1):59-71. doi:10.18537/mskn.17.01.04
BibTeX
@article{Herrerias2026,
author = {Herrerias, Celia Gallardo},
title = {Impact of augmented reality and virtual reality on mathematical learning in students with ASD and ADHD},
journal = {Maskana},
year = {2026},
volume = {17},
number = {1},
pages = {59--71},
doi = {10.18537/mskn.17.01.04}
}
EUVIMED